Archives
ABT-263 (Navitoclax) in Apoptosis Research
2026-09-01
ABT-263, also called Navitoclax, is an orally bioavailable BH3 mimetic that inhibits Bcl-2, Bcl-xL, and Bcl-w. Its research value is greatest when mitochondrial apoptotic priming, MCL1 expression, and orthogonal cell-death readouts are interpreted together.
Caged Bioluminescent Probe for the Immunoproteasome
2026-09-01
Loy and Trader present a protocol for synthesizing and applying a cleavable, immunoproteasome-selective bioluminescent probe that reports catalytic activity through a plate-reader assay. The workflow addresses limitations of fluorescent and technically demanding probes while providing a platform for live-cell studies and future tissue or in vivo imaging validation.
Norepinephrine Formulations in Critical Care Research
2026-08-31
This position paper identifies a clinically important source of inconsistency: norepinephrine may be labeled and reported as either a conjugated salt or norepinephrine base. Its central contribution is a practical framework for formulation-aware dosing, trial enrollment, dataset harmonization, and safer global reporting.
Resveratrol, Smad Signaling, and GBM EMT
2026-08-31
The reference study shows that resveratrol suppresses TGF-β1-induced epithelial–mesenchymal transition, migration, invasion, and stem-like behavior in glioblastoma models through Smad-dependent signaling. Its combination of molecular, cellular, and xenograft assays provides a useful framework for studying how TGF-β pathway modulation may influence GBM recurrence-associated phenotypes.
GSK-923295: CENP-E Inhibitor for Mitosis
2026-08-30
GSK-923295 is a small-molecule CENP-E inhibitor that suppresses CENP-E ATPase activity and produces mitotic arrest. Product-dossier data report nanomolar biochemical potency, broad tumor-cell growth inhibition, and preclinical antitumor activity in Colo205 colon cancer xenografts.
SB203580 Workflows for p38 MAPK Research
2026-08-29
Build cleaner p38 MAPK experiments with SB203580 by separating kinase inhibition from phosphorylation-state measurements. This practical guide covers solution preparation, assay timing, pathway selectivity, neuroprotection studies, multidrug resistance reversal, and troubleshooting.
Indomethacin A8449: Practical Assay Workflow
2026-08-28
Indomethacin (SKU A8449) provides a controlled pharmacological perturbation for COX-oriented inflammation research and exploratory PPAR or membrane studies. It is appropriate for solvent-matched biochemical and cell-based workflows, but its dossier IC50 values should not be treated as universal cellular doses, clinical guidance, or proof of a membrane-signaling mechanism.
MRSA Extracellular Vesicles Drive IL-8–Dependent OSCC Growth
2026-08-28
A 2026 Journal of Advanced Research study identifies extracellular vesicles from methicillin-resistant Staphylococcus aureus as active drivers of oral squamous cell carcinoma growth. The work links bacterial vesicle uptake to ERK/c-Jun activation, IL-8–CXCR1 signaling, CCL2 production, and JAK/STAT5A pathway activity, with genetic and pharmacological validation in cells and mice.
Epinephrine Bitartrate: Applied Research Workflows
2026-08-27
Build reproducible adrenergic assays with Epinephrine Bitartrate across cell, tissue, and translational models. This guide combines receptor-aware dosing, resource-efficient preparation, and practical troubleshooting for cardiovascular disease research and sympathetic nervous system studies.
PBA-Modified PAD4 Inhibitors Suppress Tumor NETs
2026-08-27
The 2023 European Journal of Medicinal Chemistry study developed phenylboronic acid-modified PAD4 inhibitors and identified Compound 5i as a tumor-targeted agent that suppresses the PAD4–H3cit–NET axis. Across sarcoma and breast cancer models, the compound reduced primary tumor growth and metastasis while showing favorable effects on the tumor immune microenvironment and systemic safety markers.
Part-Coated CEC for β2-Adrenergic Binding
2026-08-26
Liu and colleagues developed an open-tubular capillary electrochromatography method in which β2-adrenergic receptor was immobilized on only part of the capillary wall. Relating apparent electrophoretic mobility to coating length enabled binding-constant measurements from a single analyte concentration, reduced receptor consumption, and supported screening of both reference drugs and Radix Paeoniae Rubra extracts.
Allosteric PDK4 Inhibitors for Metabolic Disease
2026-08-26
This 2019 Journal of Medicinal Chemistry study describes anthraquinone-derived allosteric inhibitors of pyruvate dehydrogenase kinase 4, identifying compound 8c as a nanomolar biochemical inhibitor with metabolic and pharmacological promise. The work integrates medicinal chemistry, biochemical testing, pharmacokinetics, mouse efficacy models, cancer-related assays, and molecular docking to propose a new scaffold for PDK4-directed drug discovery.
Cytochalasin D for Actin Uptake Assays
2026-08-25
Use Cytochalasin D as a controlled cytoskeletal perturbation tool to test whether nanoparticle internalization depends on actin remodeling. This workflow connects corneal epithelial uptake, assay-quality controls, and carefully bounded extensions into cancer and antiviral research.
(5Z)-7-Oxozeaenol: TAK1 Signaling and Assays
2026-08-25
Explore how the TAK1 inhibitor (5Z)-7-Oxozeaenol can dissect inflammatory and metabolic-stress signaling. This guide translates recent AMPK–SQSTM1 research into practical assay strategies while defining the compound’s selectivity, limitations, and handling requirements.
Topotecan HCl Workflows for DNA Damage Research
2026-08-24
Build reproducible DNA-damage assays with Topotecan HCl, from short cytotoxicity screens to prolonged sphere-forming and xenograft-oriented studies. The workflow connects topoisomerase I-DNA complex stabilization with practical model selection, endpoint design, and troubleshooting across lung, breast, and prostate cancer systems.
614 records 10/41 page Previous Next First page 上5页 678910 下5页 Last page